Glycomimetics Inc Sample Contracts
GLYCOMIMETICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20__ Debt SecuritiesIndenture • March 4th, 2022 • Glycomimetics Inc • Pharmaceutical preparations • New York
WHEREAS, for its lawful corporate purposes, the Company has duly authorized the execution and delivery of this Indenture to provide for the issuance of debt securities (hereinafter referred to as the “Securities”), in an unlimited aggregate principal amount to be issued from time to time in one or more series as in this Indenture provided, as registered Securities without coupons, to be authenticated by the certificate of the Trustee;
Standard Contracts
7,000,000 Shares GlycoMimetics, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • March 21st, 2018 • Glycomimetics Inc • Pharmaceutical preparations • New York
AND [__________], As Warrant Agent Form of Preferred Stock Warrant Agreement Dated As Of GlycoMimetics, Inc. Form of Preferred Stock Warrant AgreementPreferred Stock Warrant Agreement • March 4th, 2022 • Glycomimetics Inc • Pharmaceutical preparations • New York
This Preferred Stock Warrant Agreement (this “Agreement”), dated as of [•], between GlycoMimetics, Inc., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).
As Warrant Agent Form of Common Stock Warrant Agreement Dated As Of __________ GlycoMimetics, Inc. Form of Common Stock Warrant AgreementCommon Stock Warrant Agreement • March 4th, 2022 • Glycomimetics Inc • Pharmaceutical preparations • New York
This Common Stock Warrant Agreement (this “Agreement”), dated as of [•], between GlycoMimetics, Inc., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).
GlycoMimetics, Inc. AND [_____________], As Warrant Agent Form of Debt Securities Warrant Agreement Dated As Of [__________] GlycoMimetics, Inc. Form of Debt Securities Warrant AgreementWarrant Agreement • March 4th, 2022 • Glycomimetics Inc • Pharmaceutical preparations • New York
This Debt Securities Warrant Agreement (this “Agreement”), dated as of [•], between GlycoMimetics, Inc., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).
GLYCOMIMETICS, INC. Common Stock (par value $0.001 per share) SALES AGREEMENTSales Agreement • April 28th, 2022 • Glycomimetics Inc • Pharmaceutical preparations • New York
GlycoMimetics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
GLYCOMIMETICS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OFDebt Securities Warrant Agreement • May 17th, 2019 • Glycomimetics Inc • Pharmaceutical preparations • New York
THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [·], between GLYCOMIMETICS, INC., a Delaware corporation (the “Company”), and [·], a [corporation] [national banking association] organized and existing under the laws of [·] and having a corporate trust office in [·], as warrant agent (the “Warrant Agent”).
ContractWarrant Agreement • October 4th, 2013 • Glycomimetics Inc • Pharmaceutical preparations • California
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAW OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS EXEMPT FROM REGISTRATION.
LEASE by and between BMR-MEDICAL CENTER DRIVE LLC, a Delaware limited liability company and GLYCOMIMETICS, INC., a Delaware corporationLease • July 28th, 2014 • Glycomimetics Inc • Pharmaceutical preparations
THIS LEASE (this “Lease”) is entered into as of this 23rd day of July, 2014 (the “Execution Date”), by and between BMR-MEDICAL CENTER DRIVE LLC, a Delaware limited liability company (“Landlord”), and GLYCOMIMETICS, INC., a Delaware corporation (“Tenant”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 3rd, 2023 • Glycomimetics Inc • Pharmaceutical preparations • Maryland
This Executive Employment Agreement (the “Agreement”) is entered into effective February 10, 2023 (the “Effective Date”), by and between Chinmaya Rath and GlycoMimetics, Inc. (the “Company”).
GLYCOMIMETICS, INC. Common Stock (par value $0.001 per share) SALES AGREEMENTSales Agreement • October 7th, 2020 • Glycomimetics Inc • Pharmaceutical preparations • New York
GlycoMimetics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
GLYCOMIMETICS, INC. Common Stock Purchase WarrantCommon Stock Purchase Warrant • October 4th, 2013 • Glycomimetics Inc • Pharmaceutical preparations • Delaware
GLYCOMIMETICS, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • October 28th, 2013 • Glycomimetics Inc • Pharmaceutical preparations • Delaware
This INDEMNIFICATION AGREEMENT, dated and effective as of (this “Agreement”), is by and between GLYCOMIMETICS, INC., a Delaware corporation (the “Company” (as such definition is further expanded below)), , and, if such individual is a Director serving the Company as a representative of an entity, (each an “Indemnitee” and collectively, the “Indemnitees”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 31st, 2014 • Glycomimetics Inc • Pharmaceutical preparations • Maryland
This EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is entered into effective January 15, 2014 (the “Effective Date”), by and between Rachel K. King (“Executive”) and GLYCOMIMETICS, INC. (the “Company”).
LICENSE AGREEMENTLicense Agreement • October 31st, 2013 • Glycomimetics Inc • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT dated as of the 7th day of October, 2011 (the “Agreement”) is made between GlycoMimetics, Inc., a Delaware corporation having a place of business at 401 Professional Drive, Suite 250, Gaithersburg, Maryland 20879 (“GMI”) and Pfizer Inc., a Delaware corporation having its principal place of business at 235 East 42nd Street, New York, New York 10017 (“Pfizer”).
INDEMNIFICATION AGREEMENTIndemnification Agreement • February 18th, 2025 • Glycomimetics Inc • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of [·], 2024 between Crescent Biopharma, Inc., a Delaware corporation (the “Company”), and [·] (“Indemnitee”).
CRESCENT BIOPHARMA, INC. Restricted Stock AgreementRestricted Stock Agreement • February 18th, 2025 • Glycomimetics Inc • Pharmaceutical preparations • Delaware
SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • October 4th, 2013 • Glycomimetics Inc • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of the 20th day of October, 2009 by and among GlycoMimetics, Inc., a Delaware corporation (the “Company”), and the investors listed on Exhibit 1.01, as updated from time to time, hereto (the “Investors”) and each Person who shall, after the date hereof, acquire shares of Series A-1 Preferred Stock of the Company pursuant to (A) the Purchase Agreement (as defined below) or (B) a transfer of shares of Restricted Stock (as defined below) wherein rights under this Agreement are validly assigned, and joins in and becomes a party to this Agreement by executing and delivering to the Company a counterpart signature page in the form attached hereto and who shall be listed on an updated Exhibit 1.01, each of which is also herein referred to as an “Investor” and collectively as the “Investors.”
Amendment No. 1 to the Agreement and Plan of Merger AND REORGANIZATIONAgreement and Plan of Merger and Reorganization • February 14th, 2025 • Glycomimetics Inc • Pharmaceutical preparations
This Amendment No. 1 to Agreement and Plan of Merger and reorganization (this “Amendment”) is made as of February 14, 2025, with respect to that certain Agreement and Plan of Merger and Reorganization (the “Merger Agreement”), dated as of October 28, 2024 (the “Agreement Date”), by and among GlycoMimetics, Inc., a Delaware corporation (“Parent”), Gemini Merger Sub Corp., a Delaware corporation and wholly owned subsidiary of Parent (“First Merger Sub”), Gemini Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Parent (“Second Merger Sub” and, together with First Merger Sub, “Merger Subs”), and Crescent Biopharma, Inc. (the “Company”), a Delaware corporation. All capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to them in the Merger Agreement.
GLYCOMIMETICS, INCNonqualified Stock Option Agreement • October 4th, 2013 • Glycomimetics Inc • Pharmaceutical preparations • Delaware
GlycoMimetics, Inc., a Delaware corporation (the “Company”), hereby grants an option to purchase shares of its common stock, $.001 par value, (the “Stock”) to the optionee named below. The terms and conditions of the option are set forth in this cover sheet, in the attachment and in the Company’s 2003 Stock Incentive Plan (the “Plan”).
GLYCOMIMETICS, INC.Incentive Stock Option Agreement • October 4th, 2013 • Glycomimetics Inc • Pharmaceutical preparations • Delaware
GlycoMimetics, Inc., a Delaware corporation (the “Company”), hereby grants an option to purchase shares of its common stock, $.001 par value, (the “Stock”) to the optionee named below. The terms and conditions of the option are set forth in this cover sheet, in the attachment and in the Company’s 2003 Stock Incentive Plan (the “Plan”).
Consulting AgreementConsulting Agreement • February 18th, 2025 • Glycomimetics Inc • Pharmaceutical preparations • Delaware
This Consulting Agreement (the “Agreement”) is effective as of September 28, 2024 (the “Effective Date”), Crescent Biopharma, Inc., a Delaware corporation, with a primary place of business at 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453 (“Crescent”), and Christopher Doughty (“Consultant”). Crescent and the Consultant may be referred to herein individually as “Party” or collectively, as “Parties”.
Amended and Restated SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 14th, 2025 • Glycomimetics Inc • Pharmaceutical preparations • Delaware
This Amended and Restated SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of February 14, 2025, by and among Crescent Biopharma, Inc., a Delaware corporation (“Crescent”), GlycoMimetics, Inc., a Delaware corporation (“Parent”), and each of the Persons listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”).
LEASE AGREEMENTLease Agreement • October 4th, 2013 • Glycomimetics Inc • Pharmaceutical preparations
THIS LEASE AGREEMENT (“this Lease”) is made as of this 1st day of July, 2010, between ARE-QRS CORP., a Maryland corporation (“Landlord”), and GLYCOMIMETICS, INC., a Delaware corporation (“Tenant”).
Exhibit A CONSULTING AGREEMENTConsulting Agreement • November 13th, 2024 • Glycomimetics Inc • Pharmaceutical preparations
THIS CONSULTING AGREEMENT (the “Agreement”) by and between GlycoMimetics, Inc. (“Client”) and Edwin Rock an individual (“Consultant”) is effective as of July 31, 2024 (the “Effective Date”), subject to the terms of Section 14 below.
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND...Antibody Discovery and Option Agreement • February 18th, 2025 • Glycomimetics Inc • Pharmaceutical preparations • Massachusetts
This Antibody Discovery and Option Agreement (“Agreement”) is entered into and effective as of September 19, 2024 (the “Effective Date”), by and among Paragon Therapeutics, Inc., a Delaware corporation (“Paragon”), Parascent Holding LLC, a Delaware limited liability company (“Parascent”) and Crescent Biopharma, Inc., a Delaware corporation (“Crescent”). Paragon, Parascent and Crescent are also referred to herein individually as a “Party”, or collectively as the “Parties.”
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND...Adc Discovery and Option Agreement • February 18th, 2025 • Glycomimetics Inc • Pharmaceutical preparations • Massachusetts
This ADC Discovery and Option Agreement (“Agreement”) is entered into and effective as of October 28, 2024 (the “Effective Date”), by and among Paragon Therapeutics, Inc., a Delaware corporation (“Paragon”), Parascent Holding LLC, a Delaware limited liability company (“Parascent”) and Crescent Biopharma, Inc., a Delaware corporation (“Crescent”). Paragon, Parascent and Crescent are also referred to herein individually as a “Party”, or collectively as the “Parties.”
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • February 18th, 2025 • Glycomimetics Inc • Pharmaceutical preparations
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of [·], 2025, is entered into by and among Crescent Biopharma, Inc., a Delaware corporation (“Crescent”), GlycoMimetics, Inc., a Delaware corporation (“Parent”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Securities Purchase Agreement by and among Crescent, Parent and the Investors party thereto, dated as of October 28, 2024 (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
ContractProject Agreement • March 27th, 2024 • Glycomimetics Inc • Pharmaceutical preparations
Certain identified information has been excluded from the exhibit because it is both not material and is the type that the Registrant treats as private or confidential. Triple asterisks [***] denote exclusions.
July 30, 2024 Edwin Rock Via Email Re:Separation Agreement Dear Ed:Separation Agreement • November 13th, 2024 • Glycomimetics Inc • Pharmaceutical preparations
This letter sets forth the substance of the separation agreement (the “Agreement”) which GlycoMimetics, Inc. (the “Company”) is offering to you to aid in your employment transition.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 31st, 2014 • Glycomimetics Inc • Pharmaceutical preparations • Maryland
THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) dated as of May 19, 2003, is by and between, GLYCOMIMETICS, INC., a Delaware corporation (the “Company”) and John Magnani, Ph.D. (the “Executive”).
SECOND AMENDMENT TO LEASELease • March 27th, 2024 • Glycomimetics Inc • Pharmaceutical preparations
THIS SECOND AMENDMENT TO LEASE (this “Amendment”) is entered into as of this 20 day of April, 2018 (“Second Amendment Execution Date”), by and between BMR-MEDICAL CENTER DRIVE LLC, a Delaware limited liability company (“Landlord), and GLYCOMIMETICS, INC., a Delaware corporation (“Tenant”).
Execution Version August 7, 2024 Brian Hahn RE:RETENTION AGREEMENT AND OFFER OF REVISED SEVERANCE ELIGIBILITY Dear Brian:Retention Agreement • November 13th, 2024 • Glycomimetics Inc • Pharmaceutical preparations
Thank you for all of your contributions to GlycoMimetics, Inc. (the “Company”). Your role is critical to the next phase of the Company. Our hope is that, despite the fact that you may have other employment opportunities, you will remain employed with the Company until the Company concludes that your position is no longer required. To financially incentivize you to remain employed by the Company for this period (which we expect may be several months), we are pleased to offer you a retention bonus and enhanced severance eligibility, as summarized below.
COLLABORATION AND LICENSE AGREEMENT1Collaboration and License Agreement • February 28th, 2020 • Glycomimetics Inc • Pharmaceutical preparations • New York
This COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is entered into as of January 2, 2020 (the “Effective Date”) by and between GLYCOMIMETICS, INC., a corporation organized and existing under the laws of Delaware and having a place of business at 9708 Medical Center Drive, Rockville, MD 20850 (“GlycoMimetics”), and APOLLOMICS (HONG KONG), LIMITED, a Hong Kong entity along with its Affiliates having one of its places of business at 989 East Hillsdale Blvd. Suite 220, Foster City, CA 94404 (“Apollomics”). GlycoMimetics and Apollomics are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
CRESCENT BIOPHARMA, INC. Stock Option Agreement [Incentive stock option // nonstatutory stock option]Stock Option Agreement • February 18th, 2025 • Glycomimetics Inc • Pharmaceutical preparations
